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Background: Previous reported neurologic sequelae associated with SARS-CoV-2
infection have mainly been confined to hospital-based patients in which viral detection
was restricted to nasal/throat swabs or to IgM/IgG peripheral blood serology. Here
we describe seven cases from Brazil of outpatients with previous mild or moderate
COVID-19 who developed subacute cognitive disturbances.
Methods: From June 1 to August 15, 2020, seven individuals 18 to 60 years old, with
confirmed mild/moderate COVID-19 and findings consistent with encephalopathy who
were observed >7 days after respiratory symptom initiation, were screened for cognitive
dysfunction. Paired sera and CSF were tested for SARS-CoV-2 (IgA, IgG ELISA, and RT-
PCR). Serum and intrathecal antibody dynamics were evaluated with oligoclonal bands
and IgG index. Cognitive dysfunction was assessed by theMini-Mental State Examination
(MMSE), Montreal Cognitive Assessment (MoCA), and the Clock Drawing Test (CDT).
Results: All but one of our patients were female, and the mean age was 42.6
years. Neurologic symptoms were first reported a median of 16 days (IQR 15–33) after
initial COVID-19 symptoms. All patients had headache and altered behavior. Cognitive
dysfunction was observed mainly in phonemic verbal fluency (MoCA) with a median of
six words/min (IQR 5.25–10.75) and altered visuospatial construction with a median of
four points (IQR 4–9) (CDT). CSF pleocytosis was not detected, and only one patient was
positive for SARS-Co
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Conclusions: A subacute cognitive syndrome suggestive of SARS-CoV-2-initiated
damage to cortico-subcortical associative pathways that could not be attributed solely
to inflammation and hypoxia was present in seven individuals with mild/moderate
COVID-19.
Keywords: COVID-19, Encephalopathies, executive function, viral infection, cognitive impairment
INTRODUCTION
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-
2), the virus that causes coronavirus disease 2019 (COVID-
19), was first reported in December 2019 in Hubei province,
China (1). By May 2021, more than 160 million people were
infected by this virus worldwide and over 3.4 million died in
the most severe pandemic since the 1918 Spanish Flu (2). From
the very beginning, non-specific neurological symptoms such
as headache, confusion, and dizziness were reported during the
acute phase of COVID-19 (3). Alterations in mental status and
behavior were, at first, attributed to a direct infection by SARS-
CoV-2 or to the prolonged use of neuromuscular blockers and/or
sedative medications (4).
Researchers from the United Kingdom described the first large
multicenter investigation of neurologic parameters in SARS-
CoV-2 infection (4), followed by studies from France and Italy
(5, 6). Altered mental status was the second most frequent
manifestation noted. Most reported cases were hospital-based
and had severe COVID-19, and SARS-CoV-2 detection was
restricted to nasal/throat swabs or to IgM/IgG peripheral blood
serology. During the first COVID-19 wave, restricted evidence
was presented of neurological manifestations associated with
mild or moderate SARS-CoV-2 infection in young patients (4).
Viral dynamics in the central nervous system (CNS) was also
poorly investigated.
To address the issue of possible neurological manifestations
in mild, moderate, severe, and critical COVID-19 infections,
the NeuroCovBR study group assembled a multicenter cohort
of six neurology reference centers from three different Brazilian
administrative regions. After the first included patients, we
hypothesized that COVID-19-associated encephalopathic
conditions differed from the binomial sepsis—encephalopathy.
In support of this possibility, we now describe seven patients
from our cohort seen on an outpatient basis who developed
encephalopathy and cognitive impairment >7 days after
their first mild/moderate manifestations of COVID-19. None
had severe illness, were prescribed medications, or exhibited
metabolic dysfunctions that could link their clinical presentation
to a classic diagnosis of delirium.
METHODS
The NeuroCovBR
A consortium of investigators from six regional SARS-CoV-2
pandemic epicenters located in the Southeast, Northeast,
and Federal Districts of Brazil (NeuroCovBR) participates in
this prospective cohort neurological study. Included patients
must present with possible, probable, or confirmed SARS-
CoV-2 meningitis, encephalitis, myelitis, CNS vasculitis, acute
disseminated encephalomyelitis, Guillain–Barré syndrome,
or other acute neuropathies as defined provisionally by
Ellul (7). COVID-19 was defined and classified as mild,
moderate, severe, or critical according to the World Health
Organization (8, 9).
As a brief description of the study design, patients
are referred to the study sites’ neurologists by non-
specialists (i.e., general practitioners, infectious diseases
doctors, intensive care physicians) if any of the above
syndromes is suspected as inpatient consultant or outpatient
visits. First neurological symptoms must occur within
60 days of the first COVID-19 symptoms, regardless of
COVID-19 severity. Demographics, clinics, laboratory,
MRI, and electrophysiology tests results are collected
and stored at an electronic database designed for this
study at REDCap. Additional virology tests are done as
described below.
This study is meant to last for 2 years, and the first
enrollment occurred by June 1, 2020. It was approved by
the Universidade de São Paulo ethics committee (CAAE:
31378820.1.1001.0068) and study site ethics committees.
All patients provided written informed consent, and
their personal information is protected according to
ethical procedures.
Cognitive Impaired Patients
As provisionally defined by Ellul (7) and adopted in our
study, SARS-CoV-2 encephalitis is divided into four levels:
level 1, encephalitis, level 2, possible encephalitis, level 3,
encephalopathy, and level 4, possible encephalopathy. At level 4,
we have patients with “suspected encephalopathy (an alteration
in consciousness, cognition, personality or behavior) with no
other diagnosis apparent, but does not fulfill level 3 criteria,”
and at level 3 we additionally have “acute or sub-acute (<4
weeks) alteration in consciousness, cognition (including delirium
or coma), personality or behavior persisting for more than 24 h”
and “absence of an alternative diagnosis for symptoms” (7).
Levels 3 and 4 of SARS-CoV-2 encephalitis (or SARS-CoV-
2 encephalopathy) were the main cause of patients’ inclusion
in the first 45 days of NeuroCovBR enrollment. By that time,
we expected this clinical condition to be restricted to patients
with severe COVID-19 resembling manifestations of septic
encephalopathy similar to other infectious conditions. However,
a considerable subset of mild and moderate COVID-19 patients
presented this feature. Due to this atypia, here we describe these
patients in advance.
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SARS-CoV-2 Encephalopathy Patients
We identified seven NeuroCovBR outpatients patients seen from
June 1, 2020, to August 15, 2020, with previous confirmed
mild or moderate COVID-19, as defined by the World
Health Organization (8), who presented with SARS-CoV-2
encephalopathy at least 7 days after manifestation of COVID-19-
related symptoms (8).
Exclusion criteria for this report were previous use of
medications known to cause cognitive dysfunction (i.e.,
neuromuscular blockers, sedatives, analgesics, antipsychotics),
previous neurologic or psychiatric conditions (i.e.,
Alzheimer’s disease, Parkinson’s disease, stroke, epilepsy),
and acute metabolic dysfunction (i.e., acute or acute-on-
chronic renal failure, altered sodium, altered potassium,
hypoglycemia, hyperglycemia).
Cognitive Screening
All subjects included were screened for cognitive dysfunction
using the Mini-Mental State Examination (MMSE), Montreal
Cognitive Assessment (MoCA), and/or Clock Drawing Test
(CDT). During this first period of our study, we were only
able to perform cognitive screening tests since neuropsychology
attendance was suspended by sanitary measures. For the MMSE,
the cutoffs for cognitive impairment were 20 points for illiterates,
25 points for 1–4 years of schooling, 26 points for 5–8 years
schooling, and 28 points for 9 or more years of schooling, as
reported previously for Brazilian subjects (10). For the MoCA
test, 25 points was chosen as the cutoff for mild cognitive
impairment (11). Patients with <5 schooling years were not
submitted to this test due to low accuracy in detecting dementia
in this population (12). For the CDT, we used the algorithm
method proposed by Mendes-Santos (13), scoring drawn clocks
from 1 to 10 points. As an evaluation of visuospatial function,
scores lower than 9 were considered as evidence of visuospatial
impairment. For each of the three tests, more important than
cutoff values was the analysis of the affected cognitive domains.
This may be present in cases where the MMSE analysis was
normal while theMoCA and CDT results indicated impairments.
Laboratory Procedures
Paired serum and cerebrospinal fluid (CSF) were tested for SARS-
CoV-2 IgA and IgG antibodies by a commercial ELISA kit
(Euroimmun, Lubeck, Germany) and for SARS-CoV-2-specific
RNA by RT-PCR (RealStar RT-PCR kit, Altona Diagnostics,
Hamburg, Germany), according to themanufacturers’ directions.
Blood was tested for cell count, electrolytes, glucose, renal
and liver function, C-reactive protein, and D-dimer, by routine
laboratory protocols. Routine CSF analyses included cytologic
evaluation and biochemical evaluation, lactate measurement, and
screening for common local infectious diseases.
Serum and intrathecal samples were analyzed for oligoclonal
bands (OCBs), i.e., subfractions of IgG that are encountered in
individuals with autoimmune or infectious disorders (14, 15),
by isoelectric focusing (Hydragel 9 CSF isofocusing, Sebia, Paris,
France). Results were classified as pattern 1—no OCB detected,
pattern 2—OCB in CSF only, pattern 3—identical OCBs in CSF
and serum with additional OCBs in CSF, pattern 4—identical
OCBs in CSF and serum, and pattern 5—ladder OCBs. The IgG
index, a measurement of IgG production in serum or CSF, was
calculated as [IgG (CSF) × albumin (serum)/IgG (serum) ×
albumin (CSF)]× 100. Albumin and IgG levels were determined
by nephelometry. OCB patterns 2 and 3 and an IgG index >0.7
are indicative of intrathecal antibody production.
Neuroimage and EEG
All patients were submitted either to a brain MRI or to CT
scan, based on analysis of the attending physician and hospital
availability. The findings were evaluated by a radiologist with
training in neuroradiology. EEG was performed in all patients
according to international recommendations (16).
Statistics
Continuous data are summarized as median and interquartile
range (IQR). Categorical data are presented as counts and
percentages. Data were analyzed using SPSS version 25.0.
RESULTS
During the inclusion window, seven out of 28 patients recruited
(25%) filled inclusion criteria (Figure 1). Characteristics of the
study population are described in Table 1. Six of the seven
subjects (85.7%) were female, and the median age (IQR) was
44 (39–47) years. Five (71.4%) had comorbidities, two each
with hypertension or diabetes and one with asthma. Five were
diagnosed with mild COVID-19, and two had a moderate disease
based primarily on the presence or absence of symptoms of mild
pneumonia. Neurologic symptoms developed at a median of 16
(15–33) days after initial COVID-19 manifestations. All patients
had headache and altered behavior (reported as mild irritability
FIGURE 1 | Patients flow-chart. neurocovid, neurological manifestations of
COVID-19. Encephalopathy was defined according to the Ellul et al.




























TABLE 1 | Clinical and laboratory characteristics of patients with neurological symptoms associated with COVID-19.















1* 30 F Asthma mild 15 Headache, altered behavior,
sleep disturbance, T/S
confusion, seizure
23/30 – 4/10 / – /– / – / / – /– / + / 1 0.43
2* 47 F HT mild 16 Headache, altered behavior,
sleep disturbance, T/S
confusion
30/30 24/30 9/10 / + /– / – / / – /– / + / NA ‡ 0.44
3* 44 F – mild 33 Headache, altered behavior,
sleep disturbance, T/S
confusion
– – 4/10 / – /– / – / / – /+ / + / NA ‡ NA‡
4* 39 F – mild 52 Headache, altered behavior,
sleep disturbance
– 28/30 9/10 / – /– / – / / – /– / + / 1 0.5
5* 45 F DM mild 9 Headache, altered behavior,
sleep disturbance, T/S
confusion, altered level of
conscience
29/30 – 4/10 / – /– / – / / – /+ / + / 1 0.46
6* 53 F HAS moderate 15 Headache, altered behavior,
sleep disturbance
23/30 – 4/10 / – /– / – / / – /+ / + / 1 0.52
7† 40 M DM moderate 26 Headache, altered behavior,
T/S confusion, altered level
of conscience
17/30 9/30 1/10 / – /– / – / / – /– / + / 1 0.44
MMSE, mini-mental state examination; MoCA, montreal cognitive assessment; CDT, clock drawing test; OCB, oligoclonal bands; HT, hypertension; DM, diabetes mellitus; T/S, time and space; NA, not applied. * >8 scholar years; †<4
scholar years; ‡not enough sample to proper perform the test; OCB patterns: 1 no OCBs seen, 2 OCBs in CSF only, 3 identical OCBs in CSF and serum with extra in CSF, 4 identical OCBs in both, 5 ladder OCBs.
IgG index cut off < 0.7.
CDT points range from 1 to 10.
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or aggressiveness). Five also reported periods of time/space
confusion lasting <24 h, and six had difficulties in going to sleep
or remaining asleep.
Table 1 lists the laboratory test results. Cognitive dysfunction
was observed in all patients, mainly in phonemic verbal fluency
(MoCA) with a median of six words/min (IQR 5.25–10.75) and
visuospatial construction with a median of four points (IQR 4–
9) in the CDT. Patients 1 to 5 had normal brain MRI scans, and
patients 6 and 7 had normal brain CT scans. In addition, routine
blood and CSF analyses were all within normal limits.
Only one patient (number 2) was positive for SARS-CoV-2
by PCR, and all seven were negative for IgG and IgA anti-SARS
antibodies. In the serum, all were PCR-negative, including the
patient who was positive for SARS-CoV-2 in her CSF. Three
patients were positive for IgA antibodies, and all seven had IgG
anti-SARS-antibodies. The one patient positive for SARS by PCR
in her CSF had a score of 30/30 on her MMSE and 9/10 on her
CDT test. The results of the CDT test on all patients are shown
in Figure 2. Of the four patients who had a score of 4/10 on
their CDT test, three were IgA anti-SARS antibody-positive in
their serum. There were no apparent associations between the
PCR and antibody findings, the three neurology test results, and
the occurrence of specific symptoms. None of the patients had
an OCB pattern indicative of autoantibodies, and all had an IgG
index in the normal range.
DISCUSSION
We describe seven patients with subacute SARS-CoV-2
encephalopathy and cognitive impairment associated with
mild to moderate COVID-19. Their cognitive dysfunction was
predominantly a dysregulation of executive activities that are
associated with frontal lobe damage. Dysexecutive syndrome
typically encompasses emotional, motivational, and behavioral
symptoms, as well as cognitive deficits (17–19). There were
no signs of intrathecal antibody production or blood–brain-
barrier disruption, and MRI, EEG, and CSF findings were
unremarkable. These observations are consistent with the
existence of a syndrome related to SARS-CoV-2-induced damage
to cortico-subcortical associative pathways.
SARS-CoV-2 is an RNA virus, and as a general rule RNA
viruses remain in the circulation for only a limited time period.
By the time we designed NeuroCovBR, we employed techniques
for direct and indirect viral screening to maximize our chances to
identify evidence of virus within the CNS. However, SARS-CoV-
2 RNA was detected in only one of our patients, and no atypical
OCB patterns or an abnormal IgG index was seen. Nevertheless,
cognitive dysfunction in each of the seven cases was evident.
Other examples of virus-induced neurological impairment,
such as HIV-Associated Neurocognitive Disorder (HAND)
and Hepatitis C neurocognitive impairment (20, 21), exhibit
similarities with SARS-CoV-2 encephalopathy. In those other
infections, cognitive disturbances were not attributable only
to direct virus-induced neurological damage. Instead, they
were a consequence of a persistent subclinical inflammatory
state resulting from the host’s attempts at viral clearance
as well as to viral-induced dysfunctions in neurotransmitter
receptors that were detectable by SPECT but untraceable in
routine MRI, CSF, or EEG (20, 22). HIV, for example, is
not neurotropic but resides within lymphocytes that, acting
as Trojan horses, can cross the blood–brain barrier and
induce pro-inflammatory cytokines in the brain parenchyma
causing secondary and progressive damage. The infected
lymphocyte Trojan horse mechanism can also disrupt neuronal
communication by inducing an environment rich in reactive
oxygen species that results in both neuronal dysfunction
and cell death (6). This mechanism is also feasible for
SARS-CoV-2 infection, since the virus successfully infects
lymphocytes (23). Another possibility for invasion is by infection
of epithelial cells that express the angiotensin-converting
enzyme 2 (ACE 2) receptor. SARS-CoV-2 binding to the
ACE2 receptor is the major mechanism for viral entry into
cells (7).
Hypoxia and pro-inflammatory cytokines are possible
contributory mechanisms in SARS-CoV-2 encephalopathy
(24). The analysis of pro-inflammatory cytokines along with
neuronal biomarkers in patients with severe COVID-19
resembles alterations of the immune effector cell-associated
neurotoxicity syndrome (ICANS), a neuropsychiatry syndrome
related to chimeric antigen receptor (CAR) T cell therapy
(25, 26). ICANS is associated with a cytokine release syndrome
(CRS) (27) secondary to CAR-T cell therapy, and a plausible
SARS-CoV-2 encephalopathy mechanism could be a COVID-
19-induced CRS (28, 29). However, considering that our
patients had mild/moderate COVID-19, the hypothesis of
an immune-mediated neurotoxicity ICANS-like is not as
strong as in patients with severe COVID-19; nevertheless,
a mild persistent immune-mediated inflammatory state
(considering that neurological manifestations occurred in
median 16 days) might lead to SARS-CoV-2 delayed cognitive
disturbances as in HAND or Hepatitis C neurocognitive
impairment. This time lapse between the first COVID-
19 symptoms and the first neurological symptoms also
resembles the pathophysiological mechanisms of autoimmune
induction present for instance in viral post-infectious
polyradiculoneuritis (7).
It can be argued that neuropathology studies were not
able to identify modifications caused by SARS-CoV-2 invasion
beyond nonspecific signs of inflammation and hypoxia (24, 30).
However, a prior MRI-based study observed microstructural
damage in the cerebral cortex with possible neurogenesis
in frontal-subcortical pathways independent of COVID-19
severity (31). Thus, our findings most likely were not solely
due to inflammation or hypoxia, since those manifestations
were not major attributes in our patients. We must also
consider the possibility of a specific SARS-CoV-2-induced
mechanism resulting in CNS damage not identified by gross
pathological analysis and that can be independent of COVID-
19 severity.
Dysexecutive function is characteristic of disruptions
in frontal-subcortical circuits, large neuronal circuits that
originate in the frontal cortex but spread to many different
cerebral areas such as the striatum and thalami (32).
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FIGURE 2 | Clock drowing test and phnemic verval fluency from patients with neurological symptoms associated with COVID-19. PVF, phonemic verbal fluney. PVF
cut off ≥11 words in a minute.
Considering our patients’ impairments in verbal fluency,
poor constructional strategies, and behavior alterations,
the dorsolateral prefrontal circuit, the anterior cingulate
cortex, and the lateral orbitofrontal circuit are likely the
most affected regions in SARS-CoV-2 encephalopathy. These
circuits have been associated with different types of subcortical
infectious dementia and hypothesized as affected in COVID-19
(32, 33).
Our study has limitations. We lack data on the time course
of patients’ recovery from COVID-19 and on long-term follow-
up of cognitive alterations. Although none of our patients
were oxygen-dependent and D-dimer was unremarkable as
CSF lactate, we cannot definitively rule out an underlying
mechanism of brain microcapillary dysfunction associated
with brain tissue hypoxia and neuroglycopenia in sepsis. The
observation that six of our seven subjects were female suggests a
possible gender bias in SARS-CoV-2-related adverse neurological
sequelae. However, this finding may be due solely to our
small sample size and additional studies are needed to evaluate
this further.
In conclusion, our results are compatible with subacute
cognitive dysfunctions associated with mild/moderate COVID-
19 that develops in patients independent of identifiable
comorbidities. The dysfunctions cannot be explained solely
by inflammation or hypoxia, although these effects might
contribute to the observed alterations. Our findings point to
the existence of a SARS-CoV-2-induced damage of cortico-
subcortical associative pathways whose natural history
remains unknown.
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